With a market capitalization of $163 billion, Danaher Corporation (DHR) is a global science and technology innovator that designs, manufactures and markets professional, medical, research and industrial products in the United States, China and around the world. Operating through its biotechnology, life sciences and diagnostics segments, the company provides advanced tools, technologies and services that support healthcare, scientific research and industrial applications.
Companies valued at $10 billion or more are generally considered “large cap” stocks, and Danaher fits this bill perfectly. Headquartered in Washington, District of Columbia, Danaher has built a strong presence across diverse industries, partnering with leading organizations to drive innovation in diagnostics, therapeutics and applied solutions.
Shares of the medical and industrial device maker have fallen 10.6% from their 52-week high of $258.23. Over the past three months, its shares have risen 11.1%, lagging the Health Care Select Sector SPDR Fund’s (XLV) rise of 16.6% over the same period.
Longer term, DHR stock is up marginally so far this year, lagging XLV’s 15.4% return. Additionally, the company’s shares have fallen 2.9% over the past 52 weeks, compared to XLV’s rise of 9.2% over the same time period.
The stock has been trading above its 50- and 200-day moving averages since October.
Danaher shares rose 5.9% on October 21 after the company reported better-than-expected third-quarter 2025 adjusted EPS of $1.89 and revenue of $6.05 billion. Investor sentiment was further boosted by 4.5% year-over-year revenue growth to $6.1 billion, strong bioprocessing momentum and better-than-expected respiratory revenue at Cepheid. Additionally, Danaher maintained its full-year adjusted EPS outlook of between $7.70 and $7.80.
However, DHR stock has performed weaker than its rival, IDEXX Laboratories, Inc. (IDXX). IDXX stock is up 85.4% year to date and 78.9% over the past 52 weeks.
Despite the stock’s weak performance over the past year, analysts remain optimistic about its prospects. The stock has a “Strong Buy” consensus rating from 21 analysts in coverage, and the average price target of $251.68 is a 9.1% premium to current levels.
As of the date of publication, Sohini Mondal had no (directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are for informational purposes only. This article was originally published on Barchart.com